Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
If appeals dont pan out or youre exploring other routes, there are alternative solutions to consider
The methodology included: Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America Product mapping across short-acting GLP-1 agonists, long-acting GLP-1 agonists, dual-action therapies (GLP-1/GIP), and emerging tri-agonist candidates Analysis of reported and modeled annual revenues specific to GLP-1 drug portfolios Coverage of manufacturers representing 75-80% of global market share in 2024 Extrapolation using bottom-up (prescription volume ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across drug type (short-acting, long-acting, dual-action), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), indication (type 2 diabetes, obesity, cardiovascular diseases), and administration route (subcutaneous injection, oral, inhalation) Download Free Sample Kindly complete the form below to receive a free sample of this Report This is really good guys
10.1016/j.cell.2018.07.048 39 DishyV.Cohen PourM.FeldmanL.NaftaliT.BaumerM.EfratiS.et al (2004)
Serious side effects are rare but should be addressed promptly if they occur
